Skip to main content
Clinical Trials/ACTRN12622000243718
ACTRN12622000243718
Not yet recruiting
未知

Comparative assessment of anti-diabetic efficacy of metformin plus dapagliflozin with metformin plus insulin- sensitizer or secretagogues in patients with diabetes mellitus type-2 in Pakistan: A randomized trial.

Dr. Malik Hassan Mehmood0 sites84 target enrollmentFebruary 10, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr. Malik Hassan Mehmood
Enrollment
84
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 10, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr. Malik Hassan Mehmood

Eligibility Criteria

Inclusion Criteria

  • 1\) Subject having Type\-2 diabetes mellitus
  • 2\) Both Male \& Female
  • 3\)Patients having glycated hemoglobin ranging between 6\.5 to 12\.5%
  • 4\)Age from 30 to 80 year
  • 5\)BMI greater than 23 kg/m^2
  • 6\)Patients who can understand and give consent for study

Exclusion Criteria

  • 1\)Patients not using any oral anti diabetic combination from previous 4 weeks.
  • 2\)Subject having type 1 diabetes mellitus.
  • 3\)Person with history of blood pressure greater than 180 mm of Hg
  • 4\)Pregnancy
  • 5\)Patients with renal insufficiency
  • 6\) Lactating females
  • 7\) Dementia

Outcomes

Primary Outcomes

Not specified

Similar Trials